Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cisplatin liposomal · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cisplatin liposomal 24 mg/m2 | EXPERIMENTAL | Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles. |
| Cisplatin liposomal 36 mg/m2 | EXPERIMENTAL | The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2 |
| Name | Type | Description |
|---|---|---|
| Cisplatin liposomal | DRUG | - |
Inclusion Criteria: * Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung * Patients with histologically proven, fully malignant high-grade osteosarcoma of bone * Measureable pulmonary metastases * Less than grade 3 neuropathies, insignificant decreases in...